Thomas Matthes

Dr. Thomas Matthes


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2023 in Cells
Verified
Journal Article
Open access
PDF file
SHSanae EL HARANE
Sanae EL HARANE
BZBochra zidi
Bochra zidi
NHNadia El Harane
Nadia El Harane
KKKrause Karl-Heinz
Krause Karl-Heinz
TMThomas Matthes
Thomas Matthes
OPOlivier Preynat-Seauve
Olivier Preynat-Seauve
Spheroids and organoids are important novel players in medical and life science research. They are gradually replacing two-dimensional (2D) cell cultures. Indeed, three-dimensional (3D) cultures are closer to the in vivo reality and open promising perspectives for academic research, drug screening, and personalized medicine. A large variety of cells and tissues, including tumor cells, can be the starting material for the generation of 3D cultures, including primary tissues, stem cells, or cell lines. A panoply of methods has been developed to generate 3D structures, including spontaneous or forced cell aggregation, air–liquid interface conditions, low cell attachment supports, magnetic levitation, and scaffold-based technologies. The choice of the most appropriate method depends on (i) the origin of the tissue, (ii) the presence or absence of a disease, and (iii) the intended application. This review summarizes methods and approaches for the generation of cancer spheroids and organoids, including their advantages and limitations. We also highlight some of the challenges and unresolved issues in the field of cancer spheroids and organoids, and discuss possible therapeutic applications.

17 December 2008 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JRJean‐Marie Ramirez
Jean‐Marie Ramirez
OSOlivier Schaad
Olivier Schaad
Stephane DurualStephane Durual
Stephane Durual
DCDominique Cossali
Dominique Cossali
MDMylène Docquier
Mylène Docquier
TMThomas Matthes
Thomas Matthes
Summary: The disturbed erythropoiesis in patients with refractory anaemia with ring‐sideroblasts (RARS) is characterized by intramedullary apoptosis of erythroid precursors and increased iron accumulation in mitochondria. To gain insight into these pathophysiological mechanisms we compared the gene expression profile (GEP) of erythroid precursors from RARS patients to the GEP of normal erythroid precursors. Three hundred sixty four probe sets were up‐, and 253 probe sets downregulated in RARS cells. Interestingly, Growth Differentiation factor 15 (GDF15), a cytokine from the TGFβ family, was dramatically upregulated in all RARS patients. Measurement of GDF15 in the sera from twenty RARS patients confirmed this finding by showing significantly, 7·2‐fold, increased protein levels (3254 ± 1400 ng/ml vs. 451 ± 87 ng/ml in normals). In vitro studies demonstrated erythroid‐specific production of GDF15 and dependence on erythropoietin. Induction of apoptosis by arsenic trioxide, a drug which acts via reduction of the mitochondrial membrane potential, also stimulated GDF15 production. Downregulation of endogenous GDF15 production in erythoblasts by specific siRNA led to diminished erythroid differentiation. Taken together, our findings demonstrate a new role for GDF15 in normal erythropoiesis as well as in the ineffective erythropoiesis of RARS patients.

1 September 2016 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
TMThomas Matthes
Thomas Matthes
BMBenoit Manfroi
Benoit Manfroi
BHbertrand huard
bertrand huard

11 September 2024 in Nature Cancer
Verified
Journal Article
Open access
PDF file
LCLaura Carretero-Iglesia
Laura Carretero-Iglesia
OHOlivia J. Hall
Olivia J. Hall
JBJérémy Berret
Jérémy Berret
DPDaniela Pais
Daniela Pais
CECarole Estoppey
Carole Estoppey
MPMaria Pihlgren
Maria Pihlgren
Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) co-targeting BCMA and CD38 designed to improve cytotoxicity against multiple myeloma. Targeting of two tumor-associated antigens by a single TCE resulted in superior cytotoxic potency across a variable range of BCMA and CD38 tumor expression profiles mimicking natural tumor heterogeneity, improved resistance to competing soluble factors and exhibited superior cytotoxic potency on patient-derived samples and in mouse models. Despite the broad expression of CD38 across human tissues, ISB 2001 demonstrated a reduced T cell activation profile in the absence of tumor cells when compared to TCEs targeting CD38 only. To determine an optimal first-in-human dose for the ongoing clinical trial (NCT05862012), we developed an innovative quantitative systems pharmacology model leveraging preclinical data, using a minimum pharmacologically active dose approach, therefore reducing patient exposure to subefficacious doses of therapies.

1 October 2004 in Blood
Verified
Journal Article
Closed access
PDF file
TMThomas Matthes
Thomas Matthes
PAPatricia Aguilar-Martinez
Patricia Aguilar-Martinez
LPLoredana Pizzi-Bosman
Loredana Pizzi-Bosman
RDRégIs Darbellay
RégIs Darbellay
LRLaura Rubbia-Brandt
Laura Rubbia-Brandt
PBPhotis Beris
Photis Beris
Juvenile hereditary hemochromatosis is a genetically heterogeneous disorder transmitted as an autosomal recessive trait. It is most often caused by mutations in the HJV gene and rarely in the HAMP gene. Hepcidin is considered to constitute a negative regulator of iron absorption, and its production is increased in inflammatory states and iron overload. We report the detection of a new mutation in the HAMP gene leading to juvenile hemochromatosis in 2 members of a Portuguese family. The mutation lies in the 5′-UTR (untranslated region) of the gene and creates a new initiation codon in the context of a Kozak sequence. We found no trace of hepcidin protein in the patients' urine, suggesting that ribosomes select the mutant initiation codon for translation. The decrease of hepcidin production would thus lead to increased iron absorption, resulting in iron deposition in parenchymal tissues. Phlebotomy therapy of the 2 patients resulted in impressive clinical improvement. (Blood. 2004;104: 2181-2183)

8 July 2022 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
SGSonja Giger
Sonja Giger
MHMoritz Hofer
Moritz Hofer
MMMarijana Miljkovic-Licina
Marijana Miljkovic-Licina
SHSylke Hoehnel-Ka
Sylke Hoehnel-Ka
NBNathalie Brandenberg
Nathalie Brandenberg
MLMatthias Lutolf
Matthias Lutolf
In many leukemia patients, a poor prognosis is attributed either to the development of chemotherapy resistance by leukemic stem cells (LSCs) or to the inefficient engraftment of transplanted hematopoietic stem/progenitor cells (HSPCs) into the bone marrow (BM). Here, we build a 3D in vitro model system of bone marrow organoids (BMOs) that recapitulate several structural and cellular components of native BM. These organoids are formed in a high-throughput manner from the aggregation of endothelial and mesenchymal cells within hydrogel microwells. Accordingly, the mesenchymal compartment shows partial maintenance of its self-renewal and multilineage potential, while endothelial cells self-organize into an interconnected vessel-like network. Intriguingly, such an endothelial compartment enhances the recruitment of HSPCs in a chemokine ligand/receptor-dependent manner, reminiscent of HSPC homing behavior in vivo. Additionally, we also model LSC migration and nesting in BMOs, thus highlighting the potential of this system as a well accessible and scalable preclinical model for candidate drug screening and patient-specific assays.